Earnings summaries and quarterly performance for Aligos Therapeutics.
Executive leadership at Aligos Therapeutics.
Lawrence Blatt
Detailed
President and Chief Executive Officer
CEO
HA
Hardean Achneck
Detailed
Executive Vice President, Chief Medical Officer
JS
Julian Symons
Detailed
Executive Vice President, Chief Scientific Officer
LC
Lesley Calhoun
Detailed
Executive Vice President, Chief Operating Officer and Chief Financial Officer
Board of directors at Aligos Therapeutics.
Research analysts covering Aligos Therapeutics.
Recent press releases and 8-K filings for ALGS.
Aligos Therapeutics Provides Pipeline Update at Jefferies London Healthcare Conference
ALGS
New Projects/Investments
- Aligos Therapeutics' lead program, pevifoscorvir (pevi), for chronic hepatitis B (HBV) is in a large Phase II pipeline. It has demonstrated superior efficacy in reducing HBV DNA and surface antigen compared to standard-of-care nucleoside analogs, with 100% of E-negative patients achieving below 10 HBV DNA by week 48 in studies, and is the first and only capsid assembly modulator to show effects on cccDNA. The company expects to announce the interim analysis for the Phase II study early next year.
- The company's drug ALG-009, a beta thyroid agonist for MASH, has completed Phase II-A testing, showing almost a doubling of fat reduction compared to resmetirom in a 12-week study and is ready for Phase II-B.
- Aligos also has a pan-coronavirus protease inhibitor undergoing a Phase II study in the U.K., funded by the MRC, and preclinical antisense oligonucleotide programs targeting HBV and hepatitis delta virus.
Nov 17, 2025, 3:00 PM
Aligos Therapeutics Provides Pipeline Update at Jefferies London Healthcare Conference
ALGS
New Projects/Investments
Product Launch
- Aligos Therapeutics presented its large Phase 2 pipeline, with the lead program being PEVY/PhosCovir (ALG-000184) for chronic Hepatitis B (HBV).
- PEVY demonstrated superior HBV DNA reduction compared to standard of care nucleoside analogs, achieving 100% of E-negative patients below the quantitative limit by week 48 in a long-term study, and showed reduction in HBV surface antigen, indicating an effect on cccDNA.
- The drug exhibited no drug resistance as a monotherapy and maintained antigen reductions after stopping therapy, reinforcing its impact on cccDNA.
- A Phase 2 clinical study comparing PEVY to TDF is underway, with an interim analysis expected early next year and the top-line readout in 2027.
- Aligos also highlighted ALG-009, a beta thyroid agonist for MASH, which completed Phase 2a testing, showing almost a doubling of fat reduction compared to resmetirom in a 12-week study and potential for combination with incretins for weight loss.
Nov 17, 2025, 3:00 PM
Aligos Therapeutics Provides Update on Phase 2 Pipeline at Jefferies London Healthcare Conference 2025
ALGS
New Projects/Investments
Guidance Update
- Aligos Therapeutics is advancing a large Phase 2 pipeline, highlighted by its lead program, PEVY/PhosCovir (PEVY), for chronic hepatitis B (HBV) infection, and ALG-009 for MASH and obesity.
- PEVY demonstrated superior HBV DNA reduction compared to standard of care, with 100% of E negative patients and 60% of E positive patients achieving HBV DNA below 10 at week 48/96 in long-term studies. It also showed antigen reductions and maintained off-treatment responses indicating cccDNA reduction, alongside an excellent safety profile.
- A Phase 2 clinical study for PEVY is currently underway, comparing it to TDF, with an interim analysis announcement expected early next year and top-line results anticipated in 2027.
- ALG-009 for MASH completed a Phase 2a study, achieving almost a doubling of fat reduction compared to resmetirom in a 12-week period. New data also suggests its potential to block metabolic adaptation when combined with incretins for weight loss.
Nov 17, 2025, 3:00 PM
Aligos Therapeutics Reports Q3 2025 Financial Results and Business Progress
ALGS
Earnings
New Projects/Investments
Guidance Update
- Aligos Therapeutics reported cash, cash equivalents, and investments totaling $99.1 million as of September 30, 2025, which is expected to fund planned operations into the third quarter of 2026.
- The company posted a net loss of $31.5 million for the third quarter of 2025, compared to a net loss of $19.3 million for the same period in 2024.
- Research and development expenses increased to $23.9 million in Q3 2025 from $16.8 million in Q3 2024, primarily due to increased third-party expenses for the pevifoscorvir sodium Phase 2a clinical trial.
- The Phase 2 B-SUPREME study for pevifoscorvir sodium dosed its first patient in August 2025, with interim data projected in 1H and 2H 2026.
- Aligos is evaluating options, including potential out-licensing, for ALG-055009 following preclinical data demonstrating synergistic effects in body weight loss when combined with incretin receptor agonists.
Nov 6, 2025, 1:30 PM
Aligos Therapeutics Reports Q3 2025 Financial Results and Business Progress
ALGS
Earnings
Guidance Update
New Projects/Investments
- Aligos Therapeutics reported a net loss of $31.5 million or $(3.04) per common share for the third quarter of 2025.
- As of September 30, 2025, cash, cash equivalents, and investments totaled $99.1 million, which is projected to fund planned operations into the third quarter of 2026.
- The Phase 2 B-SUPREME study for pevifoscorvir sodium in chronic HBV infection dosed its first patient in August 2025, with interim data expected in 1H and 2H 2026 and topline data in 2027.
- Preclinical data for ALG-055009 demonstrated synergistic effects in body weight loss when combined with incretin receptor agonists, and the company is exploring options for continued development, including potential out-licensing.
Nov 6, 2025, 1:30 PM
Alagos Therapeutics Discusses Lead Programs PEVY for HBV and ALG-055009 for MASH at H.C. Wainwright Conference
ALGS
New Projects/Investments
M&A
- Alagos Therapeutics is advancing pevifoscovir (PEVY), a next-generation capsid assembly modulator for chronic hepatitis B virus (CHB) infection, which demonstrates picomolar potency and a dual mechanism of action, including direct effects on reducing cccDNA.
- In a 96-week study, PEVY achieved 100% viral suppression (below 10 international units of HBV DNA) in e-negative patients and 60% in e-positive patients at week 48, with e-positive patients reaching 100% by week 96.
- The company has initiated the Phase 2 b-SUPREME trial for PEVY, designed as a monotherapy superiority study, with interim analyses expected in 2026 and top-line data in 2027.
- Alagos is also developing ALG-055009, a thyroid hormone receptor beta agonist for MASH, which is 50 to 100 times more potent than Resmetirom and showed up to a 46% reduction in fat in a Phase 2a study.
- The company is currently in partnering discussions for ALG-055009, with an announcement hoped for in the first half of next year, and sees a potential role for the drug in obesity in combination with incretins.
Oct 21, 2025, 11:00 AM
Aligos Therapeutics Provides Updates on PEVI for HBV and ALG-055009 for MASH
ALGS
New Projects/Investments
Guidance Update
M&A
- Aligos Therapeutics is developing PEVI/PHOSCOVIR (PEVI) for chronic hepatitis B virus (CHB), which achieved a 100% response rate (patients below 10 IU of HBV DNA) in both E antigen negative and positive patients at 96 weeks in a prior study.
- The B Supreme Phase II study for PEVI has commenced across 14 countries, with regulatory acceptance for chronic suppression as the primary endpoint; interim analyses are projected for H1 2026 and top-line data for 2027.
- For metabolic dysfunction-associated steatohepatitis (MASH), Aligos is advancing ALG-055009, a thyroid hormone receptor beta agonist that demonstrated up to a 46% reduction in fat in a Phase IIa study, approximately double the efficacy of resmetirom in a comparable study.
- Aligos is actively pursuing partnering discussions for ALG-055009, with an anticipated deal announcement in the first half of 2026.
Oct 21, 2025, 11:00 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more